Feasibility of single low-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a single-centre case series
Abstract
Background: Olanzapine works well as an antiemetic; however, it causes significant somnolence during the day and has additional side effects when used at a standard dose. Our goal was to evaluate the safety and effectiveness of low-dose olanzapine in patients with different cancers following highly emetogenic treatment.
Patients and Methods: This study was a retrospective, single-centre study in an Indian comprehensive cancer centre. Eight patients between the ages of 46 and 70 receiving cisplatin, a high emetogenic chemotherapy (HEC) drug, were chosen for different types of cancers and had an Eastern Cooperative Oncology Group performance level of 0–2. Patients underwent chemotherapy after receiving a prophylactic low-dose oral olanzapine regimen (2·5 mg) in conjunction with a triple antiemetic treatment. In the overall phase (0–120 hours), complete response (CR) and complete control (CC) were the major endpoints. The secondary outcome assessed safety according to the Common Terminology Criteria for Adverse Events V5.0 (CTCAE V5.0).
Results: All the studied patients were reported to have CR and CC. According to CTCAE v5.0, adverse effects grades varied from 0 to 1.
Interpretation: According to this study, prophylactic single low-dosage olanzapine (2·5 mg) was effective enough to prevent vomiting and nausea and reduce the incidence and severity of side effects in patients undergoing HEG; therefore, it should be deemed a new benchmark of care.
Keywords: Olanzapine, Cisplatin, Chemotherapy, Complete Control, Complete Response
Keywords:
olanzapine, Cisplatin, chemotherapy, complete control, complete responseDOI
https://doi.org/10.22270/jddt.v14i12.6924References
1. Gupta K, Walton R, Kataria SP. Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends. Cancer Treat Res Commun. 2021;26:100278. DOI: https://doi.org/10.1016/j.ctarc.2020.100278.
2. Razvi Y, Chan S, McFarlane T et al. ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Supportive Care in Cancer 2019;27:87-95. DOI: https://doi.org/10.1007/s00520-018-4464-y.
3. Vaid AK, Gupta S, Doval DC, et al. Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. Front Oncol. 2020;10:400. DOI: https://doi.org/10.3389/fonc.2020.00400.
4. Chiu L, Chiu N, Chow R, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study. Ann Palliat Med. 2016;5(3):172-8. DOI: https://doi.org/10.21037/apm.2016.04.05.
5. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of ChemotherapyInduced Nausea and Vomiting. N Engl J Med. 2016;375(2):134-42. DOI: https://doi.org/10.1056/NEJMoa1515725.
6. Hesketh PJ, Kris MG, Basch E et al. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology 2021;38(24):2782-2797. DOI: https://doi.org/10.1200/JCO.20.01296.
7. Yamamoto S, Iihara H, Uozumi R, Kawazoe H, Tanaka K, Fujita Y, et al. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer. 2021;21(1):832. DOI: https://doi.org/10.1186/s12885-021-08572-3.
8. An Y, Li ZH, Chen F, et al. Efficacy of 5 mg Olanzapine in the Prevention and Treatment of Carboplatin-Induced Nausea and Vomiting in the Chinese Population. Indian Journal of Pharmaceutical Sciences 2022;1:220-225. DOI: https:/doi.org/10.36468/pharmaceutical-sciences.spl.436.
9. Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, Mates M, Hsu T, McGee S, Freedman O, Kumar V, Fergusson D, Hutton B, Vandermeer L, Hilton J. A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting. Breast. 2020;54:278-285. DOI: https:/doi.org/10.1016/j.breast.2020.11.002.
10. Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N,Narahara H, Aoki D, Kimura E, Kato H, Shimokawa M. et al. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic cancer by the CINV Study Group of Japan. Gynecol. Oncol. 2016; 140: 559–64. DOI: https:/doi.org/10.1016/j.ygyno.2015.12.029.
11. Aapro M. CINV: Still troubling patients after all these years. Support. Care Cancer. 2018; 26(1):5–9. DOI: https:/doi.org/10.1007/s00520-018-4131-3.
12. Ranganath P, Einhorn L, Albany C. Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy. Biomed. Res. Int. 2015. DOI: https:/doi.org/10.1155/2015/943618.
13. Tanaka K, Inui N,Karayama M, Yasui H,Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, NakamuraY, et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer ChemotherPharmacol. 2019; 84: 147–153. DOI: https:/doi.org/10.1007/s00280-019-03868-5.
14. Navari R.M, Qin R, Ruddy K.J, Liu H, Powell S.F, Bajaj M, Dietrich L, Biggs D,Lafky J.M, Loprinzi C.L. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N. Engl. J. Med. 2016; 375: 134–142. DOI: https:/doi.org/10.1056/NEJMoa1515725
15. Zhang X.-L, Ying J.-E. Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug. Curr. Oncol. 2022; 29: 8235–8243. DOI: https://doi.org/10.3390/ curroncol29110650.
16. Bajpai J, Kapu V, Rath S, Kumar S, Sekar A, Patil P, Siddiqui A, Anne S, Pawar A, Srinivas S, Bhargava P, Gulia S, Noronha V, Joshi A, Prabhash K, Banavali S, Sarin R, Badwe R, Gupta S. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2024;25(2):246-254. DOI: https://doi.org/10.1016/S1470-2045(23)00628-9.
Published
Abstract Display: 400 
PDF Downloads: 347 PDF Downloads: 54 How to Cite
Issue
Section
Copyright (c) 2024 Harish Kamaraj, Naveenraj Viswanathan, Ardhra Jiju, R V Viknesh, Dr. Ram Abhinav Kannan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.